A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.655
Abstract: Cabotegravir is an investigational integrase inhibitor in development for the treatment and pre‐exposure prophylaxis of HIV‐1 infection. Liver disease is a major cause of morbidity and mortality in HIV‐infected individuals and can impact the pharmacokinetics… read more here.
Keywords: cabotegravir; phase study; impairment healthy; hepatic impairment ... See more keywords
Miniature mass spectrometer–based point-of-care assay for cabotegravir and rilpivirine in whole blood
Sign Up to like & getrecommendations! Published in 2022 at "Analytical and Bioanalytical Chemistry"
DOI: 10.1007/s00216-022-03954-3
Abstract: HIV prevention and treatment with injectable cabotegravir and/or rilpivirine administered once every 4 to 8 weeks is an attractive alternative to daily therapy. Prescribed dosage and drug concentrations in plasma are based on patient data… read more here.
Keywords: miniature; cabotegravir rilpivirine; mass; cabotegravir ... See more keywords
Multidimensional Electron Diffraction-Microscopy of Cabotegravir Nanocrystals
Sign Up to like & getrecommendations! Published in 2019 at "Microscopy and Microanalysis"
DOI: 10.1017/s1431927619010444
Abstract: Low-solubility active pharmaceutical ingredients (APIs) are increasingly formulated as nanosuspensions comprising pure API nanocrystals (i.e. d50 ~ 100 nm) stabilized by surfactants or polymeric steric stabilizers [1]. The physicochemical properties of such nanosuspensions are characterized… read more here.
Keywords: diffraction microscopy; microscopy; electron diffraction; electron ... See more keywords
Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles
Sign Up to like & getrecommendations! Published in 2022 at "ACS Omega"
DOI: 10.1021/acsomega.1c07260
Abstract: Cabotegravir is one of the newly approved human immunodeficiency virus (HIV) integrase enzyme inhibitors used for the prevention and treatment of HIV infection. It is the first approved long-acting injectable antiretroviral therapy for HIV and… read more here.
Keywords: cabotegravir; development; design; method ... See more keywords
Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac673
Abstract: Abstract A novel injectable pre-exposure prophylaxis, cabotegravir, has greater efficacy and acceptability than oral tenofovir/emtricitabine for prevention of HIV infection. Cabotegravir is currently priced at $22 200 per year, >185 times higher than the $60–$119… read more here.
Keywords: exposure prophylaxis; hiv; pre exposure; cabotegravir ... See more keywords
Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the American Association of Nurse Practitioners"
DOI: 10.1097/jxx.0000000000000729
Abstract: ABSTRACT The FDA recently approved a unique treatment regimen for management of HIV-1 infection in adults. A one-time per month injection of cabotegravir/rilpivirine can replace a current, stable antiretroviral regimen in those with virologic suppression,… read more here.
Keywords: infection adults; cabotegravir rilpivirine; hiv infection; cabotegravir ... See more keywords
A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15477
Abstract: Cabotegravir delivered as a long‐acting intramuscular injection has shown superior efficacy to oral tenofovir‐emtricitabine as pre‐exposure prophylaxis (PrEP) for HIV. Cabotegravir pharmacokinetics (PK), like those of other long‐acting depot preparations, exhibit variability between individuals and… read more here.
Keywords: hiv; cabotegravir; population pharmacokinetic; long acting ... See more keywords
Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir
Sign Up to like & getrecommendations! Published in 2021 at "Molecules"
DOI: 10.3390/molecules26237178
Abstract: The long-acting parenteral formulation of the HIV integrase inhibitor cabotegravir (GSK744) is currently being developed to prevent HIV infections, benefiting from infrequent dosing and high efficacy. The crystal structure can affect the bioavailability and efficacy… read more here.
Keywords: crystal structures; stability evaluation; stability; cabotegravir ... See more keywords